Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

program for ENMD-2076 is expanding with the addition of the myeloma clinical study announced earlier and with this new study in patients with leukemia. Also, plans are underway to expand the solid tumor study at the maximum tolerated dose of ENMD-2076 to further define the objectives of safety, pharmacokinetics and antitumor activity. We believe the current clinical program allows us to quickly add new patients to establish the potential of ENMD-2076 and provide a focus for Phase 2 development. These data serve as a foundation to continue discussions with potential development partners for ENMD-2076."

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... recent discussions with certain shareholders representing approximately 45% of ... dealing with certain matters including the appointment of auditors ... March 26, 2015 (the "Meeting") it intends to adjourn ... take place when the Meeting reconvenes. The Meeting will ...
(Date:3/25/2015)... UK (PRWEB) March 25, 2015 ... uptake of smartphones have fuelled social media growth, ... being currently engaged in social networking. Insurance companies ... to communicate with clients and promote a diversity ... globe over are increasingly exploiting social networking services ...
(Date:3/25/2015)... 2015 Laboratory workers can turn ... Analytical Balances to get best-performing features while still ... balances from the trusted brand include: , ... your efficiency by providing a large weighing surface ... modes include parts counting, percent weighing, checkweighing, animal/dynamic ...
(Date:3/25/2015)... Mass. and REYKJAVIK, Iceland , ... capabilities for using the genome to create better medicine, today ... the largest studies of whole-genome data yet undertaken. ... Nature Genetics – are built around the most ... a team of deCODE scientists led by Kari Stefansson ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2
... http://www.thirdbiotech.com ), a biotechnology incubator and life ... the ThirdBiotech Research,Group including a drug discovery ... of collaborative activities between researchers,and industry for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070911/LATU119LOGO ), "Over ...
... 25 The U.S. Food and Drug,Administration ... Drugs,voted to recommend the approval of tolvaptan, ... treatment,for patients with hyponatremia., "Otsuka is ... the,potential approval of tolvaptan, an investigational selective,V2-vasopressin ...
... is,strengthening its customer-focused biomarker services portfolio to,pharmaceutical, ... Xie will lead those efforts as Battelle,s ... a suite of biomarker services, including biomarker,discovery, ... clients,better define molecular mechanisms of diseases, toxicity, ...
Cached Biology Technology:ThirdBiotech Launches Research Institute to Promote Formation and Growth of Arizona-Based Biotech Companies 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2Battelle Selects Xie to Develop Biomarker Services 2
(Date:3/18/2015)... 2015 As mobile payments become more ... wallets and apps continue to be introduced into the market ... mobile payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), ... (NASDAQ: FB ) NXT-ID, Inc. (NASDAQ: ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March 17, ... here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost & ... - http://photos.prnewswire.com/prnh/20150311/181111 Biometric companies ... compete in several different markets and industries. This ... witnessing an uptrend. Join Frost ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... "male lumpectomy"a minimally invasive interventional radiology treatment for ... diseased tumors and can be considered a first-line ... particularly those who have failed radiation, according to ... 34th Annual Scientific Meeting. Additionally, the use of ...
... SAN DIEGO, Calif. (March 9, 2009)Osteoplastya highly ... painful effects of metastatic bone disease by ... immediate and substantial pain relief, often presenting ... miraculous so-called "Lazarus effect," according to researchers ...
... has taken a significant step forward today (09 March) ... tissue in rats. The team of scientists is ... (BBSRC) and led by Dr Mike Modo of the ... carried out at the Institute of Psychiatry and University ...
Cached Biology News:Freezing prostate cancer does a man's body good 2Freezing prostate cancer does a man's body good 3Freezing prostate cancer does a man's body good 4Freezing prostate cancer does a man's body good 5Metastatic bone disease patients can walk in Lazarus' footsteps 2Metastatic bone disease patients can walk in Lazarus' footsteps 3Stem cells replace stroke-damaged tissue in rats 2
Request Info...
...
... blotted protein on PVDF membrane or with ... N-terminal sequence of proteins (5-20 residues) can ... HPLC or mono-and bidimensional SDS-PAGE, followed by ... the well known EDMAN degradation method. Pre-treatment ...
albumin from bovine serum (BSA), Texas Red® conjugate...
Biology Products: